Supplementary materials: Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

<b>These are peer-reviewed supplementary materials for the article '</b><b>Cost–consequence analysis of ofatumumab </b><b>for the treatment of relapsing-remitting </b><b>multiple sclerosis in Canada</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Table 1: </b>Annual natural history transition probabilities (%) for EDSS states<b>Supplementary Table 2: </b>EDSS-dependent mortality multiplier and disability weights for MS and number of hospitalization days per year<b>Supplementary Table 3: </b>Productivity loss per year due to MS<b>Supplementary Table 4: </b>Treatment efficacy and discontinuation probabilities for ofatumumab and comparators versus BSC from the network meta-analysis<b>Supplementary Table 5:</b> Costs by health state<b>Supplementary Table 6:</b> Drug administration, monitoring, and adverse event costs<b>Supplementary Table 7: </b>Drug administration costs<b>Supplementary Table 8: </b>Drug monitoring costs<b>Supplementary Figure 1: </b>Patient time (in years) in each EDSS health state over 10 years for first-line and second-line treatments without treatment switching or delay. <b>Supplementary Figure 2: </b>YLD and YLL over 10 years for all first-line and second-line treatments without treatment switching or delay.<b>Supplementary Figure 3: </b>Sensitivity Analysis results for Ofatumumab versus Ocrelizumab at 10-years.<b>Supplementary Figure 4: </b>Sensitivity Analysis results for Ofatumumab versus Teriflunomide at 10-years.<b>Supplementary Figure 5: </b>Sensitivity Analysis results for Ofatumumab versus Dimethyl Fumarate at 10-years. <b>Supplementary Figure 6: </b>Sensitivity Analysis results for Ofatumumab versus Glatiramer Acetate at 10-years. <b>Supplementary Figure 7: </b>Sensitivity Analysis results for Ofatumumab versus Avonex at 10-years. <b>Supplementary Figure 8: </b>Sensitivity Analysis results for Ofatumumab versus Rebif 44 at 10-years. <b>Supplementary Figure 9: </b>Sensitivity Analysis results for Ofatumumab versus Betaseron at 10-years. <b>Supplementary Figure 10: </b>Sensitivity Analysis results for Ofatumumab versus Extavia at 10-years. <b>Supplementary Figure 11: </b>Sensitivity Analysis results for Ofatumumab versus BSC at 10-years. <b>Supplementary Figure 12: </b>Sensitivity Analysis results for Ofatumumab versus Cladribine at 10-years. <b>Supplementary Figure 13: </b>Sensitivity Analysis results for Ofatumumab versus Natalizumab at 10-years. <b>Supplementary Figure 14: </b>Sensitivity Analysis results for Ofatumumab versus Fingolimod at 10-years. <b>Aim:</b> The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. <b>Materials &amp; methods:</b> A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5 years following switch from commonly used first-line therapies. <b>Results: </b>Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes. <b>Conclusion:</b> Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.